FDA green-lights addiction drug amid opioid controversy

The FDA has said repeatedly that it's committed to fighting the opioid epidemic, and to that end, it approved BioDelivery Sciences' ($BDSI) Bunavail Friday to treat dependence on the drugs. BioDelivery said it expects to launch the new med late in this year's third quarter, and its market currently tallies more than two million people in the U.S. The FDA has recently had to answer for its move to keep potent opioid painkiller Zohydro on the market despite worries that it lends itself to abuse. Since the controversy bubbled up, the agency has also approved Evzio, an EpiPen-like handheld device containing a drug that can reverse the effects of an overdose. Story | More